HQL
Income statement / Annual
Last year (2024), Tekla Life Sciences Investors's total revenue was $86.69 M,
an increase of 120.10% from the previous year.
In 2024, Tekla Life Sciences Investors's net income was $85.30 M.
See Tekla Life Sciences Investors,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
| Operating Revenue |
$86.69 M |
$39.39 M |
$31.86 M |
$45.02 M |
$39.07 M |
$2.44 M |
$1.99 M |
$69.81 M |
$6.29 M |
$1.32 M |
| Cost of Revenue |
$0.00
|
$5.24 M
|
$5.55 M
|
$6.08 M
|
$5.21 M
|
$0.00
|
$0.00
|
$4.61 M
|
$4.95 M
|
$5.65 M
|
| Gross Profit |
$86.69 M
|
$18.28 M
|
$26.31 M
|
$38.95 M
|
$33.87 M
|
$2.44 M
|
$1.99 M
|
$65.20 M
|
$1.34 M
|
-$4.33 M
|
| Gross Profit Ratio |
1
|
0.46
|
0.83
|
0.87
|
0.87
|
1
|
1
|
0.93
|
0.21
|
-3.27
|
| Research and Development Expenses |
$0.00
|
$0.00
|
-$3.28
|
$0.00
|
$3.15
|
$0.00
|
$0.00
|
$1.46
|
-$1.89
|
$0.00
|
| General & Administrative Expenses |
$1.33 M
|
$903.14 K
|
$1.08 M
|
$844.02 K
|
$751.32 K
|
$5.32 M
|
$5.59 M
|
$991.51 K
|
$5.23 M
|
$6.04 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.33 M
|
$903.14 K
|
$1.08 M
|
$844.02 K
|
$751.32 K
|
$5.32 M
|
$5.59 M
|
$991.51 K
|
-$1.89
|
$6.04 M
|
| Other Expenses |
$56.66 K
|
$268.31 K
|
$275.97 K
|
$313.69 K
|
$278.66 K
|
$0.00
|
$0.00
|
$423.33 K
|
$20.74 M
|
$143.44 K
|
| Operating Expenses |
$1.39 M
|
$1.17 M
|
$1.35 M
|
$1.16 M
|
$1.03 M
|
$5.32 M
|
$5.59 M
|
$1.26 M
|
$13.35 M
|
$39.18 M
|
| Cost And Expenses |
$1.39 M
|
$17.03 M
|
$136.47 M
|
-$19.51 M
|
-$83.99 M
|
$5.32 M
|
$5.59 M
|
$5.56 M
|
$1.34 M
|
$39.18 M
|
| Interest Income |
$1.04 M
|
$204.45 K
|
$50.09 K
|
$0.00
|
$164.80 K
|
$0.00
|
$0.00
|
$90.56 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$45.22 M
|
| Depreciation & Amortization |
$1.92 M
|
$27.60 M
|
$2.99 M
|
$4.14 M
|
$0.00
|
$2.88 M
|
$3.61 M
|
$3.88 M
|
$3.79 M
|
$4.72 M
|
| EBITDA |
$87.22 M |
$49.95 M |
-$101.62 M |
$68.68 M |
$123.06 M |
$0.00 |
$0.00 |
$68.56 M |
$0.00 |
$0.00 |
| EBITDA Ratio |
1.01
|
1.27
|
-3.19
|
1.53
|
3.15
|
0
|
0
|
0.98
|
0
|
0
|
| Operating Income Ratio |
0.98
|
-0.13
|
-3.28
|
1.43
|
3.15
|
-1.18
|
-1.82
|
-0.06
|
-0.6
|
-3.57
|
| Total Other Income/Expenses Net |
$87.22 M
|
$27.60 M
|
$2.42 K
|
-$7.83 K
|
-$11.18 K
|
-$67.60 M
|
$32.27 M
|
$72.74 M
|
-$8.12 M
|
$45.22 M
|
| Income Before Tax |
$85.30 M
|
$22.35 M
|
-$104.60 M
|
$64.53 M
|
$123.05 M
|
-$70.48 M
|
$28.66 M
|
$68.56 M
|
-$11.91 M
|
$40.50 M
|
| Income Before Tax Ratio |
0.98
|
0.57
|
-3.28
|
1.43
|
3.15
|
-28.88
|
14.43
|
0.98
|
-1.89
|
30.62
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.00
|
$0.00
|
$0.00
|
| Net Income |
$85.30 M
|
$22.35 M
|
-$104.60 M
|
$64.53 M
|
$123.05 M
|
-$70.48 M
|
$28.66 M
|
$68.56 M
|
-$11.91 M
|
$40.50 M
|
| Net Income Ratio |
0.98
|
0.57
|
-3.28
|
1.43
|
3.15
|
-28.88
|
14.43
|
0.98
|
-1.89
|
30.62
|
| EPS |
3.04 |
0.79 |
-4.07 |
2.66 |
5.16 |
-3.04 |
1.28 |
3.21 |
1 |
2.06 |
| EPS Diluted |
3.04 |
0.79 |
-4.07 |
2.66 |
5.16 |
-3.04 |
1.28 |
3.21 |
-0.57 |
2.06 |
| Weighted Average Shares Out |
$28.06 M
|
$28.29 M
|
$25.68 M
|
$24.26 M
|
$23.85 M
|
$23.18 M
|
$22.41 M
|
$21.36 M
|
$11.91 M
|
$19.69 M
|
| Weighted Average Shares Out Diluted |
$28.06 M
|
$28.29 M
|
$25.68 M
|
$24.26 M
|
$23.85 M
|
$23.18 M
|
$22.41 M
|
$21.36 M
|
$20.74 M
|
$19.69 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
